文献速递类风湿关节炎

Mavrilimumab与Golimumab治疗类风湿关节炎的随机IIb期研究

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2018-01-01

这项24周双盲IIb期研究将DMARD-IR和/或抗TNF-IR的活动性RA患者随机分配至mavrilimumab 100mg每2周或golimumab 50mg每4周组,均联用甲氨蝶呤。主要终点为第24周ACR20/50/70、DAS28-CRP<2.6、HAQ DI改善>0.22及安全性。研究未设计正式比较两组疗效,结果显示两种治疗均具临床疗效且耐受良好。

要点

  • mavrilimumab 100mg每2周与golimumab 50mg每4周均联用甲氨蝶呤,在DMARD-IR和/或抗TNF-IR的RA患者中显示临床疗效。
  • 第24周ACR20/50/70两组差异的90%CI均跨越0,研究未设计正式比较两种治疗。
  • 治疗中出现不良事件率mavrilimumab组51.4%、golimumab组42.6%,无死亡及特定安全信号。

核心结论

  • mavrilimumab 100mg每2周和golimumab 50mg每4周在DMARD-IR和/或抗TNF-IR的RA患者中均显示临床疗效且耐受良好。

研究设计与样本

  • 24周、IIb期、双盲随机研究,活动性RA患者按1:1随机接受mavrilimumab 100mg皮下每2周或golimumab 50mg皮下每4周交替安慰剂,均联用甲氨蝶呤。
  • mavrilimumab组n=70,golimumab组n=68;研究未设计正式比较两种治疗。

主要发现

  • 第24周全部患者中,mavrilimumab组与golimumab组ACR20、ACR50、ACR70应答率差异分别为-3.5%(90%CI -16.8, 9.8)、-8.6%(90%CI -22.0, 4.8)、-9.8%(90%CI -21.1, 1.4)。
  • 抗TNF-IR亚组中,两组ACR20、ACR50、ACR70应答率差异分别为11.1%(90%CI -7.8, 29.9)、-8.7%(90%CI -28.1, 10.7)、-0.7%(90%CI -18.0, 16.7)。
  • 第24周DAS28-CRP<2.6达标率差异在全部患者中为-11.6%(90%CI -23.2, 0.0),在抗TNF-IR亚组中为-4.0%(90%CI -20.9, 12.9)。
  • 第24周HAQ DI改善>0.22的患者比例两组相似。
  • 治疗中出现不良事件率mavrilimumab组51.4%、golimumab组42.6%,无死亡,未发现特定安全信号。

关键数值与推荐

  • 主要终点包括第24周ACR20、ACR50、ACR70应答率,DAS28-CRP<2.6达标率,HAQ DI改善>0.22比例及安全性/耐受性。
  • DMARD-IR定义为≥1种方案失败;抗TNF-IR定义为1-2种方案失败。
  • mavrilimumab剂量为100mg皮下每2周;golimumab剂量为50mg皮下每4周交替安慰剂。

临床怎么用

  • 对于DMARD-IR和/或抗TNF-IR的活动性RA患者,mavrilimumab 100mg每2周或golimumab 50mg每4周联用甲氨蝶呤均可考虑为治疗选择。
  • 因研究未设计正式比较两种治疗,临床选择需结合患者个体情况与安全性特征。

局限性

  • 研究未设计正式比较mavrilimumab与golimumab的疗效。
  • 样本量较小(mavrilimumab组n=70,golimumab组n=68),研究周期为24周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This 24-week, phase IIb, double-blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte-macrophage colony-stimulating factor receptor α) and golimumab (a monoclonal antibody to tumor necrosis factor [anti-TNF]) in patients with rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) (referred to as DMARD-IR) and/or inadequate response to other anti-TNF agents (referred to as anti-TNF-IR). METHODS: Patients with active RA and a history of DMARD-IR (≥1 failed regimen) or DMARD-IR (≥1 failed regimen) and anti-TNF-IR (1-2 failed regimens) were randomized 1:1 to receive either mavrilimumab 100 mg subcutaneously every other week or golimumab 50 mg subcutaneously every 4 weeks alternating with placebo every 4 weeks, administered concomitantly with methotrexate. The primary end points were the American College of Rheumatology 20% improvement (ACR20), 50% improvement, and 70% improvement response rates at week 24, percentage of patients achieving a Disease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) of <2.6 at week 24, percentage of patients with a score improvement of >0.22 on the Health Assessment Questionnaire (HAQ) disability index (DI) at week 24, and safety/tolerability measures. This study was not powered to formally compare the 2 treatments. RESULTS: At week 24, differences in the ACR20, ACR50, and ACR70 response rates between the mavrilimumab treatment group (n = 70) and golimumab treatment group (n = 68) were as follows: in all patients, -3.5% (90% confidence interval [90% CI] -16.8, 9.8), -8.6% (90% CI -22.0, 4.8), and -9.8% (90% CI -21.1, 1.4), respectively; in the anti-TNF-IR group, 11.1% (90% CI -7.8, 29.9), -8.7% (90% CI -28.1, 10.7), and -0.7% (90% CI -18.0, 16.7), respectively. Differences in the percentage of patients achieving a DAS28-CRP of <2.6 at week 24 between the mavrilimumab and golimumab groups were -11.6% (90% CI -23.2, 0.0) in all patients, and -4.0% (90% CI -20.9, 12.9) in the anti-TNF-IR group. The percentage of patients achieving a >0.22 improvement in the HAQ DI score at week 24 was similar between the treatment groups. Treatment-emergent adverse events were reported in 51.4% of mavrilimumab-treated patients and 42.6% of golimumab-treated patients. No deaths were reported, and no specific safety signals were identified. CONCLUSION: The findings of this study demonstrate the clinical efficacy of both treatments, mavrilimumab at a dosage of 100 mg every other week and golimumab at a dosage of 50 mg every 4 weeks, in patients with RA. Both regimens were well-tolerated in patients who had shown an inadequate response to DMARDs and/or other anti-TNF agents.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Weinblatt ME, McInnes IB, Kremer JM, et al. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis Rheumatol. 2018. PMID: 28941039. doi:10.1002/art.40323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。